DOC

Longer Gleevec use extends GIST patient survival

By Elaine Brown,2014-11-05 02:54
31 views 0
Taking the Novartis cancer drug Gleevec for three years following surgery to remove gastrointestinal stromal tumors (GIST) extended survival in more high-risk patients than the standard one year of Gleevec treatment, according to data released on Sunday
null
null

Report this document

For any questions or suggestions please email
cust-service@docsford.com